Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

ThermoGenesis Corp

ThermoGenesis Holdings, Inc. is an industry leader in the development and commercialization of automated cell process... read more Featured Products: More products

Download Mobile App





ThermoGenesis’ Breakthrough Lateral Flow Immunoassay Test Reader to Help Track Antibody Response of COVID-19 Vaccine Recipients

By LabMedica International staff writers
Posted on 21 Oct 2020
A new breakthrough lateral flow immunoassay test reader technology aims to facilitate the widespread use of inexpensive, mass-produced, FDA-authorized SARS-CoV-2 lateral flow immunoassay (LFIA) tests to distinguish seropositive members of populations of concern (individuals who already have SARS-CoV-2 antibodies), who might be a lower priority for the earliest immunization.

The ThermoGenesis Reader from ThermoGenesis Holdings, Inc. More...
(Rancho Cordova, CA, USA) has been specifically designed to facilitate the efficient utilization of COVID-19 vaccine stocks in the US as we enter 'The Vaccine Era' of COVID-19 response. According to the Centers for Disease Control and Prevention (CDC), only 15 million doses of COVID-19 vaccine might be available three months after the first vaccine is approved. ThermoGenesis has designed its new reader technology in anticipation of the potential need for a 'seronegatives first' triage strategy while vaccine supplies are limited. Seronegative members of the populations of concern (individuals altogether lacking SARS-CoV-2 antibodies) could be prioritized. ThermoGenesis Reader will also enable the tracking of vaccine recipients' antibody response over time, both to presumptively confirm immune status and to determine when booster immunizations may be required by individuals whose initial vaccine responses are waning.

ThermoGenesis plans to complete current beta testing of its new reader and enter into production in December, in time for the anticipated approval of one or more vaccines around the end of this year. The company has also received notification from the US Patent and Trademark Office (USPTO) of its intent to issue a patent for the company's new breakthrough lateral flow immunoassay test reader technology.

"We have consulted with leading public health experts from industry, government and academia who have advised us that US Food and Drug Administration (FDA) authorization of the first COVID-19 vaccines won't be the beginning of the end of this pandemic, but rather the end of the beginning," said Chris Xu, Ph.D., Chief Executive Officer of ThermoGenesis. "The challenge we are addressing comes in anticipation of an initially limited vaccine supply that will be administered on a prioritized basis to only a small fraction of the population. Our innovative technology, the ThermoGenesis Reader, is a robust, inexpensive, widely deployable, easy-to-use solution that will enable the tracking of vaccine recipients' antibody response over time, both to presumptively confirm immune status and to determine when booster immunizations may be required by individuals whose initial vaccine responses are waning. Lateral flow immunoassays are the fastest, least expensive, and most readily mass-produced serological tests for the kind of high-volume testing this will require, and the portable precision of the ThermoGenesis Reader will unleash LFIA's power to help carry us through to the ultimate eradication of this virus through an optimally efficient immunization strategy."

Related Links:
ThermoGenesis Holdings, Inc.


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.